Anixa Biosciences, Inc. (ANIX)
2.76
+0.01
(+0.36%)
USD |
NASDAQ |
Sep 11, 16:00
2.775
+0.02
(+0.54%)
After-Hours: 20:00
Anixa Biosciences Enterprise Value : 80.49M for Sept. 11, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| September 11, 2026 | 80.49M |
| September 10, 2026 | 80.15M |
| September 09, 2026 | 82.91M |
| September 08, 2026 | 85.34M |
| September 04, 2026 | 91.21M |
| September 03, 2026 | 90.52M |
| September 02, 2026 | 93.29M |
| September 01, 2026 | 98.48M |
| August 31, 2026 | 100.90M |
| August 28, 2026 | 105.39M |
| August 27, 2026 | 109.54M |
| August 26, 2026 | 109.72M |
| August 25, 2026 | 111.62M |
| August 24, 2026 | 110.24M |
| August 21, 2026 | 113.35M |
| August 20, 2026 | 109.20M |
| August 19, 2026 | 113.35M |
| August 18, 2026 | 103.66M |
| August 17, 2026 | 105.74M |
| August 14, 2026 | 95.02M |
| August 13, 2026 | 95.71M |
| August 12, 2026 | 96.75M |
| August 11, 2026 | 96.40M |
| August 10, 2026 | 97.44M |
| August 07, 2026 | 103.32M |
| Date | Value |
|---|---|
| August 06, 2026 | 103.66M |
| August 05, 2026 | 102.97M |
| August 04, 2026 | 102.97M |
| August 03, 2026 | 102.97M |
| July 31, 2026 | 103.32M |
| July 30, 2026 | 106.01M |
| July 29, 2026 | 103.30M |
| July 28, 2026 | 104.66M |
| July 27, 2026 | 102.62M |
| July 24, 2026 | 110.76M |
| July 23, 2026 | 112.46M |
| July 22, 2026 | 104.66M |
| July 21, 2026 | 106.01M |
| July 20, 2026 | 102.62M |
| July 17, 2026 | 100.58M |
| July 16, 2026 | 97.87M |
| July 15, 2026 | 103.98M |
| July 14, 2026 | 93.46M |
| July 13, 2026 | 89.05M |
| July 10, 2026 | 89.05M |
| July 09, 2026 | 94.48M |
| July 08, 2026 | 90.75M |
| July 07, 2026 | 85.66M |
| July 06, 2026 | 88.71M |
| July 02, 2026 | 96.17M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Arrowhead Pharmaceuticals, Inc. | 11.47B |
| Oncolytics Biotech, Inc. | 89.25M |
| Sangamo Therapeutics, Inc. | 53.27M |
| Sarepta Therapeutics, Inc. | 2.417B |
| Vicapsys Life Sciences, Inc. | 32.86M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -2.625M |
| Total Expenses (Quarterly) | 2.606M |
| EPS Diluted (Quarterly) | -0.0762 |
| Earnings Yield | -11.23% |
| Normalized Earnings Yield | -11.23 |